Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $77,874.30 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $77,874.30. Following the transaction, the insider owned 7,069 shares of the company’s stock, valued at $390,420.87. This trade represents a 16.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher John Kenney also recently made the following trade(s):

• On Tuesday, March 10th, Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81.

Xenon Pharmaceuticals Trading Down 4.6%

Xenon Pharmaceuticals stock opened at $55.23 on Monday. The company has a fifty day simple moving average of $43.71 and a 200-day simple moving average of $41.96. The stock has a market cap of $4.59 billion, a P/E ratio of -12.67 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the firm earned ($0.84) earnings per share. As a group, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on XENE shares. Wolfe Research started coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Wedbush upped their price target on Xenon Pharmaceuticals from $47.00 to $64.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Morgan Stanley set a $97.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Finally, Needham & Company LLC boosted their price objective on shares of Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $71.94.

Institutional Trading of Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Neo Ivy Capital Management purchased a new position in Xenon Pharmaceuticals during the 3rd quarter worth approximately $2,001,000. JPMorgan Chase & Co. lifted its stake in Xenon Pharmaceuticals by 11.3% in the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after buying an additional 142,452 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Xenon Pharmaceuticals by 4.6% in the third quarter. Westfield Capital Management Co. LP now owns 1,206,066 shares of the biopharmaceutical company’s stock valued at $48,424,000 after buying an additional 53,461 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Xenon Pharmaceuticals by 34.6% in the second quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock valued at $31,934,000 after acquiring an additional 262,109 shares during the period. Finally, American Century Companies Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $21,280,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.